Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Tenaya Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Hoey Timothy (Chief Scientific Officer) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Sold 4,007 shares @ $3.81, valued at $15.3k
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/18/2023 4 PATTERSON LEONE D (Chief Fin. and Bus. Officer) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Sold 4,452 shares @ $3.81, valued at $17k
08/18/2023 4 Ali Faraz (CEO) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Sold 5,563 shares @ $3.81, valued at $21.2k
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Million; Runway to Fund Operations into First Half 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the second quarter ended June 30, 2023. “We are looking ahead..."
06/12/2023 4 Walsh Jeffrey T. (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Williams R Sanders (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Stehman-Breen Catherine (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Srivastava Deepak (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Parschauer Karah Herdman (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Lee June (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 GOEDDEL DAVID V (10% Owner) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 CHEN JIN-LONG (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 29,532 options to buy @ $7.12, valued at $210.3k
06/12/2023 4 Burroughs Amy L. (Director) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Granted 14,766 options to buy @ $7.12, valued at $105.1k
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Certificate of Amendment to THE Amended and Restated Certificate of Incorporation of TENAYA THERAPEUTICS, Inc.",
"TENAYA THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1. Introduction. The purpose of this Tenaya Therapeutics, Inc. Executive Change in Control and Severance Plan is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other than for death, Disability, or Cause or voluntarily terminated for Good Reason under the circumstances described in the Plan. This Plan is an “employee welfare benefit plan,” as defined in Section 3 of ERISA. This document is both the written instrument under which the Plan is maintained and the required summary plan description for the Plan. 2. Important Terms. The following words and phrases, when the initial letter of the..."
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN FRANCISCO, Calif., May 10, 2023 -- Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the first quarter ended March 31, 2023. “Tenaya is making ..."
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/08/2023 10-K Annual Report for the period ended December 31, 2022
03/08/2023 8-K Quarterly results
Docs: "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update TN-201 IND Cleared in January; Plan to Begin Phase 1b Dosing in MYBPC3-associated HCM Patients in Third Quarter 2023 Dosing Commenced in Multiple-Ascending Dose Stage of First-In-Human Clinical Trial of TN-301; Data Anticipated in Second Half 2023 2022 Year End Cash and Investments of $204 Million; Runway to Fund Operations into First Half 2025 South San Francisco, Calif. – March 8, 2023 – Tenaya Therapeutics, Inc. , a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31, 2022 and p..."
02/21/2023 SC 13D/A COLUMN GROUP III, LP reports a 17.8% stake in TENAYA THERAPEUTICS, INC.
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in Tenaya Therapeutics, Inc.
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 6.7% stake in TENAYA THERAPEUTICS INC
02/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/10/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/09/2023 SC 13G/A FMR LLC reports a 4.2% stake in TENAYA THERAPEUTICS INC
01/23/2023 4 COLUMN GROUP III GP, LP (10% Owner) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Bought 69,739 shares @ $2.4979, valued at $174.2k
01/23/2023 4 GOEDDEL DAVID V (10% Owner) has filed a Form 4 on Tenaya Therapeutics, Inc.
Txns: Bought 69,739 shares @ $2.4979, valued at $174.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy